// App-Quantinova.ai

5596 : Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.

Researchers

Presenter

  • Vicky Makker

Principal Investigators

  • Drew W. Rasco

  • Nicholas J. Vogelzang

  • Mark Messing

  • Marcia S. Brose

  • Allen Lee Cohn

  • Carol Aghajanian

  • Daniel E. Stepan

  • Corina E. Dutcus

  • Emmett V. Schmidt

  • Matthew Guo

  • Pallavi Sachdev

  • Robert Charles Shumaker

  • Matthew H. Taylor

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Rocky Mountain Cancer Center, US Oncology, Denver, CO

  • Eisai Inc, Woodcliff Lake, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • Oregon Health and Science University, Portland, OR

Locations

  • United States

Companies

  • Eisai Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Cluster of Differentiation 206

  • Microsatellite instability

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • Unknown

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02501096

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved